Drugs / AAV9-hSyn1-miGRIK2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06063850 | Jun 2024 → Nov 2026 expected | temporal lobe epilepsy | UniQure Biopharma B.V. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-06-19 | UniQure Biopharma B.V. | Results uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy gcs-web.com ↗
As of the date of the presentation, there have been no Serious Adverse Events (SAEs) related to AMT-260 or the surgical procedure reported. |
| 2025-05-29 | UniQure Biopharma B.V. | Results uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) gcs-web.com ↗ |
| 2023-09-05 | UniQure Biopharma B.V. | Regulatory uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy gcs-web.com ↗ |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-19 | UniQure Biopharma B.V. | uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy gcs-web.com ↗ |
| 2025-05-29 | UniQure Biopharma B.V. | uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) gcs-web.com ↗ |
| 2024-11-21 | UniQure Biopharma B.V. | uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy gcs-web.com ↗ |
| 2023-09-05 | UniQure Biopharma B.V. | uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy gcs-web.com ↗ |
| 2022-11-29 | UniQure Biopharma B.V. | uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event gcs-web.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV9-hSyn1-miGRIK2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06063850 ↗ |
| Known as | AMT-260 | “AMT-260 is an AAV9 gene therapy product” NCT06063850 ↗ |